On primary intracranial tumors
Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197, 2008.
Clarke JL, Iwamoto FM, Sul J, et al: Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide(Drug information on temozolomide) for newly diagnosed glioblastoma. J Clin Oncol 27:3861-3867, 2009.
Correa DD, Shi W, Thaler HT, et al: Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86:321–327, 2008.
Friedman HS, Prados MD, Wen PY, et al: Bevacizumab(Drug information on bevacizumab) alone and in combination with irinotecan(Drug information on irinotecan) in recurrent glioblastoma. J Clin Oncol 27:4733–4740, 2009.
Grossman SA, Ye X, Piantadosi S, et al: Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:2443–2449, 2010.
Iwamoto FM, Abrey LE, Beal K, et al: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206, 2009.
Keime-Guibert F, Chinot O, Taillandier L, et al: Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535, 2007.
Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745, 2009.
Perry JR, Bélanger K, Mason WP, et al: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051–2057, 2010.
Prados MD, Chang SM, Butowski N, et al: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579–584, 2009.
Quant EC, Norden AD, Drappatz J, et al: Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11:550–555, 2009.
Reardon DA, Fink KL, Mikkelsen T, et al: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610–5617, 2008.
Scott BJ, Quant EC, McNamara MB, et al: Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 12:603–607, 2010.
Stupp R, Hegi ME, Mason W, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466, 2009.
van den Bent MJ, Brandes AA, Rampling R, et al: Randomized phase II trial of erlotinib versus temozolomide or carmustine(Drug information on carmustine) in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27:1268–1274, 2009.
Verhaak RG, Hoadley KA, Purdom E. et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010.
Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972, 2010.
Wick W, Hartmann C, Engel C, et al: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine(Drug information on procarbazine), lomustine(Drug information on lomustine), and vincristine or temozolomide. J Clin Oncol 27:5874–5880, 2009.
Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009.
On primary extra-axial tumors
Korah MP, Nowlan AW, Johnstone PA, et al: Radiation therapy alone for imaging-defined meningiomas. Int J Radiat Oncol Biol Phys 76:181–186, 2010.
Yang SY, Park CK, Park SH, et al: Atypical and anaplastic meningiomas: Prognostic implication of clinicopathological features. J Neurol Neurosurg Psychiatry 79:574–580, 2008.
On metastatic brain tumors
Aoyama H, Tago M, Kato N, et al: Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68:1388–1395, 2007.
Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037–1044, 2009.
Ekenel M, Hormigo AM, Peak S, et al: Capecitabine(Drug information on capecitabine) therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223–227, 2007.
Kim JE, Lee DH, Choi Y, et al: Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65:351–354, 2009.
Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141, 2011.
Lin NU, Dieras V, Paul D, et al: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459, 2009.
Omlin A, D'Addario G, Gillessen S, et al: Activity of pemetrexed(Drug information on pemetrexed) against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer 65:383–384, 2009.
Sun A, Bae K, Gore EM, et al: Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis. J Clin Oncol 29:279-286, 2011.
Abbreviations in this chapter
BTSG = Brain Tumor Study Group; EORTC = European Organisation for Research and Treatment of Cancer; RTOG = Radiation Therapy Oncology Group